IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
66 hedge funds and large institutions have $17.9M invested in IGM Biosciences in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 32 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.87% less ownership
Funds ownership: 51.77% → 45.9% (-5.9%)
13% less capital invested
Capital invested by funds: $20.5M → $17.9M (-$2.62M)
16% less funds holding
Funds holding: 79 → 66 (-13)
56% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 32
57% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$336K |
| 2 |
Jane Street
New York
|
+$221K |
| 3 |
Renaissance Technologies
New York
|
+$101K |
| 4 |
Goldman Sachs
New York
|
+$75.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$67.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$788K |
| 2 |
State Street
Boston,
Massachusetts
|
-$510K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$489K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$259K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$132K |
IGMS Hedge Fund Activity: Q2 2025 in Review
66 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q2 2025, worth a combined $17.9M — down 13% from $20.5M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of IGMS and 10 opened new positions — a net loss of 13 holders — while 32 trimmed existing stakes and 14 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $336K. The largest seller was BlackRock, cutting an estimated $788K.
- 66 institutional investors held IGM Biosciences (IGMS) as of Q2 2025, down from 79 in Q1 2025.
- Funds reported $17.9M of IGM Biosciences stock for Q2 2025, down 13% quarter-over-quarter.
- 10 funds opened new IGM Biosciences positions in Q2 2025 and 23 closed out, a net change of -13 holders.
- The largest IGM Biosciences buyer in Q2 2025 was Millennium Management, an estimated $336K added.
- The largest IGM Biosciences seller in Q2 2025 was BlackRock, an estimated $788K sold.
Based on aggregated 13F filings for Q2 2025.